Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Jul;76(7):928–933. doi: 10.1136/jnnp.2004.048983

Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

J Lambert 1, D Mann 1, F Richard 1, J Tian 1, J Shi 1, U Thaker 1, S Merrot 1, J Harris 1, B Frigard 1, T Iwatsubo 1, C Lendon 1, P Amouyel 1
PMCID: PMC1739723  PMID: 15965197

Abstract

Background: It has been proposed that, independent of the ε4 allele, APOE promoter polymorphisms (–491 A/T and –219 G/T) may be risks factor for Alzheimer's disease by modulating APOE expression.

Objective: To measure the level of APOE expression in Alzheimer's disease.

Methods: Brains were obtained at necropsy from 114 patients with early and late onset sporadic Alzheimer's disease in Greater Manchester (UK) during years 1986 to 2001. Total RNA was extracted from 84 brains. Purified lymphocytes were obtained from fresh blood from 16 probable Alzheimer cases from Lille (France). APOE and ß-actin gene expression was determined by reverse transcriptase polymerase chain reaction in brain and lymphocytes.

Results: An inverse correlation between APOE expression level and Aß loads was observed. As previously described and extended to 114 cases here, an association between the –219 TT genotype and a higher level of parenchymal Aß deposition was found, irrespective of APOE ε4 allele status. This effect was more pronounced in older individuals, whereas higher Aß load appeared more closely related to ε4 in the younger age group (cut off point at the median age at death (72.5 years)). The –219 TT genotype was associated with a decrease in APOE expression. There was a 60% decrease in APOE expression in lymphocytes from probable Alzheimer cases v controls (p = 0.01).

Conclusions: In the oldest individuals, reduced APOE expression, modulated in part by –219 G/T polymorphism, may influence risk and constitute a determinant Aß load in Alzheimer's disease.

Full Text

The Full Text of this article is available as a PDF (120.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artiga M. J., Bullido M. J., Sastre I., Recuero M., García M. A., Aldudo J., Vázquez J., Valdivieso F. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998 Jan 9;421(2):105–108. doi: 10.1016/s0014-5793(97)01543-3. [DOI] [PubMed] [Google Scholar]
  2. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997 Nov;17(3):263–264. doi: 10.1038/ng1197-263. [DOI] [PubMed] [Google Scholar]
  3. Beffert U., Cohn J. S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J., Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999 Oct 2;843(1-2):87–94. doi: 10.1016/s0006-8993(99)01894-6. [DOI] [PubMed] [Google Scholar]
  4. Berr C., Lambert J. C., Sazdovitch V., Amouyel P., Chartier-Harlin M. C., Mohr M., Heldt N., Kiesmann M., Hauw J. J. Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiol Aging. 2001 Mar-Apr;22(2):227–235. doi: 10.1016/s0197-4580(00)00227-x. [DOI] [PubMed] [Google Scholar]
  5. Bertrand P., Poirier J., Oda T., Finch C. E., Pasinetti G. M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res. 1995 Oct;33(1):174–178. doi: 10.1016/0169-328x(95)00097-c. [DOI] [PubMed] [Google Scholar]
  6. Blennow K., Hesse C., Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 1994 Dec 20;5(18):2534–2536. doi: 10.1097/00001756-199412000-00032. [DOI] [PubMed] [Google Scholar]
  7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259. doi: 10.1007/BF00308809. [DOI] [PubMed] [Google Scholar]
  8. Bullido M. J., Artiga M. J., Recuero M., Sastre I., García M. A., Aldudo J., Lendon C., Han S. W., Morris J. C., Frank A. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998 Jan;18(1):69–71. doi: 10.1038/ng0198-69. [DOI] [PubMed] [Google Scholar]
  9. Campillos Mónica, Lamas José Ramón, García Miguel Angel, Bullido María Jesús, Valdivieso Fernando, Vázquez Jesús. Specific interaction of heterogeneous nuclear ribonucleoprotein A1 with the -219T allelic form modulates APOE promoter activity. Nucleic Acids Res. 2003 Jun 15;31(12):3063–3070. doi: 10.1093/nar/gkg435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carlsson J., Armstrong V. W., Reiber H., Felgenhauer K., Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta. 1991 Feb 15;196(2-3):167–176. doi: 10.1016/0009-8981(91)90070-s. [DOI] [PubMed] [Google Scholar]
  11. Champagne D., Pearson D., Dea D., Rochford J., Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience. 2003;121(1):99–110. doi: 10.1016/s0306-4522(03)00361-0. [DOI] [PubMed] [Google Scholar]
  12. DeMattos Ronald B., Cirrito John R., Parsadanian Maia, May Patrick C., O'Dell Mark A., Taylor Jennie W., Harmony Judith A. K., Aronow Bruce J., Bales Kelly R., Paul Steven M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004 Jan 22;41(2):193–202. doi: 10.1016/s0896-6273(03)00850-x. [DOI] [PubMed] [Google Scholar]
  13. Diedrich J. F., Minnigan H., Carp R. I., Whitaker J. N., Race R., Frey W., 2nd, Haase A. T. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol. 1991 Sep;65(9):4759–4768. doi: 10.1128/jvi.65.9.4759-4768.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., van Duijn C. M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997 Oct 22;278(16):1349–1356. [PubMed] [Google Scholar]
  15. Fukuyama R., Mizuno T., Mori S., Yanagisawa K., Nakajima K., Fushiki S. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. Eur Neurol. 2000;43(3):161–169. doi: 10.1159/000008157. [DOI] [PubMed] [Google Scholar]
  16. Gomes Luciana I., Silva Ricardo L. A., Stolf Beatriz S., Cristo Elier B., Hirata Roberto, Soares Fernando A., Reis Luiz F. L., Neves E. Jordão, Carvalho Alex F. Comparative analysis of amplified and nonamplified RNA for hybridization in cDNA microarray. Anal Biochem. 2003 Oct 15;321(2):244–251. doi: 10.1016/s0003-2697(03)00466-4. [DOI] [PubMed] [Google Scholar]
  17. Growdon W. B., Cheung B. S., Hyman B. T., Rebeck G. W. Lack of allelic imbalance in APOE epsilon3/4 brain mRNA expression in Alzheimer's disease. Neurosci Lett. 1999 Sep 10;272(2):83–86. doi: 10.1016/s0304-3940(99)00557-1. [DOI] [PubMed] [Google Scholar]
  18. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997 Apr;20(4):154–159. doi: 10.1016/s0166-2236(96)01030-2. [DOI] [PubMed] [Google Scholar]
  19. Heijmans Bastiaan T., Slagboom P. Eline, Gussekloo Jacobijn, Droog Simone, Lagaay A. Margot, Kluft Cornelis, Knook Dick L., Westendorp Rudi G. J. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet. 2002 Jan 22;107(3):201–208. doi: 10.1002/ajmg.10142. [DOI] [PubMed] [Google Scholar]
  20. Hesse C., Bogdanovic N., Davidsson P., Blennow K. A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease. Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):452–459. doi: 10.1159/000017189. [DOI] [PubMed] [Google Scholar]
  21. Hesse C., Larsson H., Fredman P., Minthon L., Andreasen N., Davidsson P., Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res. 2000 Apr;25(4):511–517. doi: 10.1023/a:1007516210548. [DOI] [PubMed] [Google Scholar]
  22. Holtzman D. M. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci. 2001 Oct;17(2):147–155. doi: 10.1385/JMN:17:2:147. [DOI] [PubMed] [Google Scholar]
  23. Koistinaho Milla, Lin Suizhen, Wu Xin, Esterman Michail, Koger Deanna, Hanson Jeffrey, Higgs Richard, Liu Feng, Malkani Seema, Bales Kelly R. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004 Jun 13;10(7):719–726. doi: 10.1038/nm1058. [DOI] [PubMed] [Google Scholar]
  24. Koudinov A. R., Berezov T. T., Koudinova N. V. Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB J. 1998 Sep;12(12):1097–1099. doi: 10.1096/fasebj.12.12.1097. [DOI] [PubMed] [Google Scholar]
  25. Kunicki S., Richardson J., Mehta P. D., Kim K. S., Zorychta E. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem. 1998 Jul;31(5):409–415. doi: 10.1016/s0009-9120(98)00027-7. [DOI] [PubMed] [Google Scholar]
  26. Lambert J-C, Araria-Goumidi L., Myllykangas L., Ellis C., Wang J. C., Bullido M. J., Harris J. M., Artiga M. J., Hernandez D., Kwon J. M. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology. 2002 Jul 9;59(1):59–66. doi: 10.1212/wnl.59.1.59. [DOI] [PubMed] [Google Scholar]
  27. Lambert J-C, Coyle N., Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. J Med Genet. 2004 Feb;41(2):104–112. doi: 10.1136/jmg.2003.005033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lambert J. C., Berr C., Pasquier F., Delacourte A., Frigard B., Cottel D., Pérez-Tur J., Mouroux V., Mohr M., Cécyre D. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet. 1998 Sep;7(9):1511–1516. doi: 10.1093/hmg/7.9.1511. [DOI] [PubMed] [Google Scholar]
  29. Lambert J. C., Brousseau T., Defosse V., Evans A., Arveiler D., Ruidavets J. B., Haas B., Cambou J. P., Luc G., Ducimetière P. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet. 2000 Jan 1;9(1):57–61. doi: 10.1093/hmg/9.1.57. [DOI] [PubMed] [Google Scholar]
  30. Lambert J. C., Mann D., Goumidi L., Harris J., Amouyel P., Iwatsubo T., Lendon C., Chartier-Harlin M. C. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet. 2001 Feb 24;357(9256):608–609. doi: 10.1016/S0140-6736(00)04063-0. [DOI] [PubMed] [Google Scholar]
  31. Lambert J. C., Pasquier F., Cottel D., Frigard B., Amouyel P., Chartier-Harlin M. C. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet. 1998 Mar;7(3):533–540. doi: 10.1093/hmg/7.3.533. [DOI] [PubMed] [Google Scholar]
  32. Lambert J. C., Pérez-Tur J., Dupire M. J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., Chartier-Harlin M. C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet. 1997 Nov;6(12):2151–2154. doi: 10.1093/hmg/6.12.2151. [DOI] [PubMed] [Google Scholar]
  33. Landén M., Hesse C., Fredman P., Regland B., Wallin A., Blennow K. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia. 1996 Sep-Oct;7(5):273–278. doi: 10.1159/000106892. [DOI] [PubMed] [Google Scholar]
  34. Laws S. M., Hone E., Taddei K., Harper C., Dean B., McClean C., Masters C., Lautenschlager N., Gandy S. E., Martins R. N. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry. 2002;7(8):886–890. doi: 10.1038/sj.mp.4001097. [DOI] [PubMed] [Google Scholar]
  35. Laws S. M., Taddei K., Martins G., Paton A., Fisher C., Clarnette R., Hallmayer J., Brooks W. S., Gandy S. E., Martins R. N. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport. 1999 Mar 17;10(4):879–882. doi: 10.1097/00001756-199903170-00038. [DOI] [PubMed] [Google Scholar]
  36. Lefranc D., Vermersch P., Dallongeville J., Daems-Monpeurt C., Petit H., Delacourte A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett. 1996 Jul 12;212(2):91–94. doi: 10.1016/0304-3940(96)12774-9. [DOI] [PubMed] [Google Scholar]
  37. Lehtimäki T., Pirttilä T., Mehta P. D., Wisniewski H. M., Frey H., Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 1995 Jan;95(1):39–42. doi: 10.1007/BF00225071. [DOI] [PubMed] [Google Scholar]
  38. Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  39. Mann D. M., Iwatsubo T., Pickering-Brown S. M., Owen F., Saido T. C., Perry R. H. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett. 1997 Jan 17;221(2-3):81–84. doi: 10.1016/s0304-3940(96)13294-8. [DOI] [PubMed] [Google Scholar]
  40. Meyer M. R., Tschanz J. T., Norton M. C., Welsh-Bohmer K. A., Steffens D. C., Wyse B. W., Breitner J. C. APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet. 1998 Aug;19(4):321–322. doi: 10.1038/1206. [DOI] [PubMed] [Google Scholar]
  41. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991 Apr;41(4):479–486. doi: 10.1212/wnl.41.4.479. [DOI] [PubMed] [Google Scholar]
  42. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61. doi: 10.1038/ng0996-55. [DOI] [PubMed] [Google Scholar]
  43. Mui S., Briggs M., Chung H., Wallace R. B., Gomez-Isla T., Rebeck G. W., Hyman B. T. A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Neurology. 1996 Jul;47(1):196–201. doi: 10.1212/wnl.47.1.196. [DOI] [PubMed] [Google Scholar]
  44. Myllykangas Liisa, Polvikoski Tuomo, Reunanen Karoliina, Wavrant-De Vrieze Fabienne, Ellis Clare, Hernandez Dena, Sulkava Raimo, Kontula Kimmo, Verkkoniemi Auli, Notkola Irma-Leena. ApoE epsilon3-haplotype modulates Alzheimer beta-amyloid deposition in the brain. Am J Med Genet. 2002 Apr 8;114(3):288–291. doi: 10.1002/ajmg.10202. [DOI] [PubMed] [Google Scholar]
  45. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., Pitas R. E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994 May 6;264(5160):850–852. doi: 10.1126/science.8171342. [DOI] [PubMed] [Google Scholar]
  46. Pahnke J., Walker L. C., Schroeder E., Vogelgesang S., Stausske D., Walther R., Warzok R. W. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. Acta Neuropathol. 2002 Nov 5;105(1):25–29. doi: 10.1007/s00401-002-0602-0. [DOI] [PubMed] [Google Scholar]
  47. Perry R. T., Collins J. S., Harrell L. E., Acton R. T., Go R. C. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet. 2001 May 8;105(4):332–342. doi: 10.1002/ajmg.1371. [DOI] [PubMed] [Google Scholar]
  48. Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J. S., Christen Y., Schoofs A., Davignon J., Poirier J. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis. 2000 Feb;7(1):23–37. doi: 10.1006/nbdi.1999.0273. [DOI] [PubMed] [Google Scholar]
  49. Rebeck G. W., Cheung B. S., Growdon W. B., Deng A., Akuthota P., Locascio J., Greenberg S. M., Hyman B. T. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett. 1999 Sep 17;272(3):155–158. doi: 10.1016/s0304-3940(99)00602-3. [DOI] [PubMed] [Google Scholar]
  50. Ricicová Markéta, Palková Zdena. Comparative analyses of Saccharomyces cerevisiae RNAs using Agilent RNA 6000 Nano Assay and agarose gel electrophoresis. FEMS Yeast Res. 2003 Oct;4(1):119–122. doi: 10.1016/S1567-1356(03)00145-4. [DOI] [PubMed] [Google Scholar]
  51. Roks G., Cruts M., Houwing-Duistermaat J. J., Dermaut B., Serneels S., Havekes L. M., Hofman A., Breteler M. M. B., Van Broeckhoven C., van Duijn C. M. Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study. Am J Med Genet. 2002 Jul 8;114(5):570–573. doi: 10.1002/ajmg.10407. [DOI] [PubMed] [Google Scholar]
  52. Rösler N., Wichart I., Bancher C., Jellinger K. A. Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia? J Neural Transm Suppl. 1996;47:259–266. doi: 10.1007/978-3-7091-6892-9_18. [DOI] [PubMed] [Google Scholar]
  53. Skoog I., Hesse C., Fredman P., Andreasson L. A., Palmertz B., Blennow K. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Arch Neurol. 1997 Mar;54(3):267–272. doi: 10.1001/archneur.1997.00550150029012. [DOI] [PubMed] [Google Scholar]
  54. Song H., Saito K., Seishima M., Noma A., Urakami K., Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett. 1997 Aug 15;231(3):175–178. doi: 10.1016/s0304-3940(97)00558-2. [DOI] [PubMed] [Google Scholar]
  55. Teter Bruce. ApoE-dependent plasticity in Alzheimer's disease. J Mol Neurosci. 2004;23(3):167–179. doi: 10.1385/JMN:23:3:167. [DOI] [PubMed] [Google Scholar]
  56. Thaker U., McDonagh A. M., Iwatsubo T., Lendon C. L., Pickering-Brown S. M., Mann D. M. A. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease. Neuropathol Appl Neurobiol. 2003 Feb;29(1):35–44. doi: 10.1046/j.1365-2990.2003.00425.x. [DOI] [PubMed] [Google Scholar]
  57. Tian J., Shi J., Bailey K., Mann D. M. A. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathol Appl Neurobiol. 2004 Feb;30(1):46–56. doi: 10.1046/j.0305-1846.2003.00510.x. [DOI] [PubMed] [Google Scholar]
  58. Tian J., Shi J., Bailey K., Mann D. M. A. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathol Appl Neurobiol. 2004 Feb;30(1):46–56. doi: 10.1046/j.0305-1846.2003.00510.x. [DOI] [PubMed] [Google Scholar]
  59. Viitanen L., Pihlajamäki J., Miettinen R., Kärkkäinen P., Vauhkonen I., Halonen P., Kareinen A., Lehto S., Laakso M. Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease. J Mol Med (Berl) 2001 Jul 25;79(12):732–737. doi: 10.1007/s001090100265. [DOI] [PubMed] [Google Scholar]
  60. Yamagata K., Urakami K., Ikeda K., Ji Y., Adachi Y., Arai H., Sasaki H., Sato K., Nakashima K. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):57–62. doi: 10.1159/000051236. [DOI] [PubMed] [Google Scholar]
  61. Yang D. S., Small D. H., Seydel U., Smith J. D., Hallmayer J., Gandy S. E., Martins R. N. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 1999;90(4):1217–1226. doi: 10.1016/s0306-4522(98)00561-2. [DOI] [PubMed] [Google Scholar]
  62. Ye Shu, Dunleavey Louise, Bannister Wendy, Day Lorna B., Tapper William, Collins Andrew R., Day Ian N. M., Simpson Iain, Southampton Atherosclerosis Study Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. Eur J Hum Genet. 2003 Jun;11(6):437–443. doi: 10.1038/sj.ejhg.5200983. [DOI] [PubMed] [Google Scholar]
  63. Zurutuza L., Verpillat P., Raux G., Hannequin D., Puel M., Belliard S., Michon A., Pothin Y., Camuzat A., Penet C. APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population. Eur J Hum Genet. 2000 Sep;8(9):713–716. doi: 10.1038/sj.ejhg.5200513. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES